Purpose: Several galectins are released by tumor cells and macrophages and accumulate in the tumor microenvironment. Galectin-1 and -3 were found to bind to glycosylated receptors at the surface of tumorinfiltrating lymphocytes (TIL), forming glycoprotein-galectin lattices that could reduce the motility and therefore the functionality of surface molecules. In contrast to blood T cells, human TIL show defective IFN-g secretion upon ex vivo stimulation. We have previously shown that extracellular galectin-3 participates in the impairment of TIL functions. Indeed, disruption of glycoprotein-galectin-3 lattices using anti-galectin-3 antibodies, or N-acetyllactosamine as a competing sugar, boosted cytokine secretion by TIL. Here we have tested a clinical grade galectin antagonist: GM-CT-01, a galactomannan obtained from guar gum reported to be safe in more than 50 patients with cancer.
Introduction
Accumulation of human tumor-infiltrating lymphocytes (TIL) is considered as a good prognostic factor (reviewed in Wie€ ers; ref. 1) . Moreover, when gene expression was analyzed in tumor samples of patients from 3 active immunization clinical trials, a gene signature, including T-cell markers, correlated with clinical responses (2) (3) (4) . However, TIL freshly isolated-without in vitro expansion-from various human tumor samples (melanomas, renal cell carcinomas, ovarian, and pancreatic carcinomas) often proved defective in lyzing relevant target cells and producing IFN-g upon stimulation. This contrasted with blood T cells isolated from the same patients, which were readily cytotoxic and showed robust IFN-g secretion (3, (5) (6) (7) (8) (9) .
Several immunosuppressive mechanisms have been proposed to explain the impaired functions of freshly isolated TIL. First, TIL can express inhibitory receptors that downmodulate T-cell activation upon antigen recognition, for example PD1, KIR, BTLA, CTLA-4, Tim-3 (10) (11) (12) (13) . Blocking these receptors with antibodies has been shown to prolong survival of T cells and to boost their proliferation upon activation in vitro. Such antibodies have also shown their efficacy in vivo, as an objective-response rate of 40% was observed in a trial where 53 patients with advanced melanoma received combined injections of ipilimumab and nivolumab targeting CTLA-4 and PD-1, respectively (14) . Second, soluble molecules present at the tumor site such as TGF-b and PGE 2 can block T-cell function or activation (15, 16) . Third, enzymes such as IDO can deplete the tumor microenvironment in tryptophane (17) . Fourth, regulatory T cells (Treg) could downmodulate antitumor responses as shown in mice depleted in Treg, which were more prone to reject tumors (18) (19) (20) .
A fifth potential mechanism is surface paralysis because of glycoprotein-galectin lattices. Galectins are lectins frequently secreted by tumor cells and macrophages (21, 22) , and extracellular galectins seem responsible for deficient T-cell functions (23) . We have shown that TIL harbor surface galectin-1 and galectin-3, and that treating TIL with N-acetyllactosamine (LacNAc) or GCS-100, 2 galectin antagonists, boosts cytokine secretion (8, 24) . It was also reported that extracellular galectin-1 and galectin-3 promote apoptosis of T cells (25) (26) (27) (28) (29) .
The identification of antigens recognized by T cells on human tumor cells has resulted in numerous clinical trials involving vaccination of tumor-bearing patients with defined tumor antigens (30) . Although new generations of vaccines might be more effective (31) , so far only 5% of the vaccinated patients with metastatic melanoma show a complete or partial clinical response (32, 33) . The tumors of the patients about to receive a vaccine already contain T cells directed against tumor antigens that are probably functionally impaired (34) (35) (36) . The low toxicity of therapeutic vaccination of cancer, provided the target antigen is tumor-specific, justifies efforts to improve its efficacy. A potential strategy could be to inject galectin antagonists so as to boost TIL function.
Because LacNAc has a very short half-life in vivo and GCS-100 was not accessible for a clinical trial, we searched for another galectin antagonist available for clinical use. We decided to test GM-CT-01, a galactomannan of plant origin that was shown to bind to galectin-1 but at a site different from the conventional galectin carbohydrate binding domain (37) . No data have been reported yet about interactions of GM-CT-01 with galectin-3. GM-CT-01 (operational name) or Davanat (trade name) is isolated from seeds of the cluster bean, Cyamopsis tetragonoloba, as guar gum, and subjected to controlled partial chemical degradation. Its size is in the range of 50 kDa and its half-life is between 12 and 18 hours as determined in Cynomolgus monkeys (P.G. Traber; personal communication). Injection of GM-CT-01 to tumorbearing mice potentiated the antitumor activity of 5-fluorouracil (38) . In tumor patients with colorectal carcinoma or cholangiocarcinoma, a phase I clinical trial was completed and 3 phase II open label clinical trials are ongoing. A total of 57 patients have been injected and a reduction of 5-fluorouracil-related side effects was described (39, 40) .
We here compared the effect of GM-CT-01 and of LacNAc on the cytotoxicity and cytokine secretion by CD8 þ and CD4 þ fresh human TIL. We also tested its therapeutic potential in a murine tumor model.
Materials and Methods
Cells, TIL, and reagents Samples of patient-derived solid tumors, tumor ascites, and blood were collected after approval by the institutional review boards of all collaborating institutions. Ascites cells were concentrated by centrifugation and either frozen at À80 C or resuspended in Iscove's modified Dulbecco medium (IMDM; Life Technologies) supplemented with 0.24 mmol/L L-asparagine, 0.55 mmol/L L-arginine, 1.5 mmol/L L-glutamine (AAG), 100 mg/mL streptomycin, 100 U/mL penicillin, and 30 mg/mL gentamycin (Sigma-Aldrich; culture medium), enriched by 2% human serum. Mononuclear cells were isolated from blood of donors without cancer, more precisely patients with hemochromatosis, or from some ascites samples by Lymphoprep (Axis-Shield PoCAS) and usually frozen at À80 C or in liquid nitrogen, in culture medium containing 10% DMSO/45% human serum. Cells were thawed for 2 hours in culture medium supplemented with 2% to 10% human serum and 5 U/mL DNase I (SigmaAldrich). T cells were isolated from blood mononuclear cells or ascites cells, by rosetting with sheep erythrocytes (BioM erieux) previously treated with 2(2-aminoethyl) isothiourea dihydrobromide (Sigma-Aldrich). CD8 þ and CD4 þ T cells were isolated by a positive selection strategy using immunomagnetic beads (AutoMACS system, Miltenyi Biotec). Purity of CD4 þ or CD8 þ T-cell preparations was between 90% and 95%. Autologous tumor cell lines were established in our laboratory from total cells, or a CD2 À fraction, isolated from tumor samples. Cell lines were cultured in IMDM supplemented with AAG, 100 mg/mL streptomycin, 100 U/mL penicillin, 1/100 fungizone (Invitrogen), and 30 mg/mL gentamycin (Sigma-Aldrich), and with 10% FBS and ACL-4. Human recombinant interleukin (IL)-2 was from Chiron Healthcare SAS, IL-7 from R&D Systems, and LacNAc from Carbosynth. GM-CT-01 was kindly provided by Anatole Klyosov from Galectin Therapeutics.
T-cell functional assays
Nonspecific T-cell stimulation was performed in roundbottomed microwells with 10,000 T cells in 200 mL culture medium containing IL-2 (6 IU/mL) as appropriate, with
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Detachment of galectins
CD8 þ T cells, isolated from the ovarian carcinoma ascites obtained from patient LB3122, were incubated at 37 C for 2 hours with LacNAc or GM-CT-01, washed, incubated at 4 C for 15 minutes with FcR Blocking Reagent (1/5; Miltenyi Biotec) diluted in PBS/BSA 0.2% (BSA, Sigma-Aldrich), washed again and incubated with 5 mg/mL of either biotinylated rat anti-galectin-3 antibody M3/38 or polyclonal rabbit anti-galectin-1 IgG (5 mg/mL; Abcam). Cells were washed and incubated at 4 C for 15 minutes with either neutravidin R-phycoerythrin conjugate (1.25 mg/mL; Invitrogen) or anti-rabbit Ig secondary antibody coupled to Alexa Fluor 488 (10 mg/mL; Invitrogen). Cells were also labeled with anti-CD3.PerCP (1/40; BD) and anti-CD8. APC (1/40; BD). After a final washing step, cells were fixed with 2% formaldehyde in PBS and analyzed on a FACSCalibur.
Fluorescence resonance energy transfer microscopy
Cells were plated at 1 to 2 Â 10 5 /cm 2 on poly-L-lysine (Sigma-Aldrich)-coated glass coverslips and allowed to bind at RT for 7 minutes, then labeled for 30 minutes on ice with anti-CD8a (UCHT-4, mouse IgG2a; SigmaAldrich) and anti-TCRb (IP-26, mouse IgG1; e-Bioscience) diluted in PBS/BSA 0.2%. After 3 washes in the same cold buffer, cells were fixed at RT for 20 minutes with 4% formaldehyde and 0.1% glutaraldehyde (Sigma-Aldrich) in 0.1 mol/L phosphate buffer, washed twice in PBS/BSA and incubated with 10 mmol/L glycine in PBS for 10 minutes, then incubated for 30 minutes on ice with an anti-IgG2a-Alexa Fluor 488 antibody [fluorescence resonance energy transfer (FRET) donor, green; Invitrogen], and an anti-IgG1-Alexa Fluor 568 antibody (FRET acceptor, red; Invitrogen) diluted in PBS/BSA. After 3 washes, cells were fixed again and coverslips were mounted onto glass slides using Prolong Gold (Invitrogen). Images were acquired with an LSM 510 laser scanning microscope and analyzed by AIM Software (Zeiss). Imaging was performed with a 488 nm line generated by an Ar laser (30 mW) and a 561 nm line generated by a DPSS laser (10 mW), both used at 1%. Acceptor photobleaching was achieved using the DPSS laser at 100% with 100 iterations. Three images were recorded before and after bleaching. To calculate the increase in donor emission (indicative of FRET efficiency), 3 regions of interest for each cell were chosen, bleached, and compared with 3 control regions in the nonbleached area. Increase in donor emission was calculated as follows: %FRET efficiency ¼ [1 À (donor intensity before bleaching/donor intensity after bleaching)] Â 100.
Results

GM-CT-01 boosts IFN-g secretion by CD8
þ TIL in a concentration-dependent manner CD8 þ T cells were isolated from human carcinoma ascites and incubated for 2 hours with increasing concentrations of GM-CT-01 or with 5 mmol/L LacNAc as a positive control. T cells were next stimulated nonspecifically by beads coated with anti-CD3 and anti-CD28 antibodies (CD3/CD28 beads) and, after 20 hours, IFN-g secretion was measured in the culture supernatant. In this representative patient, preincubation of TIL with 0.3 mmol/L ($15 mg/mL) of GM-CT-01 boosted IFN-g secretion by more than 3-fold. Halfmaximal effect was obtained at 0.4 mmol/L ($20 mg/mL; Fig. 1 ). For the experiments described below, GM-CT-01 was used at concentrations in the micromolar range (either 0.6 or 1.8 mmol/L $30 or 100 mg/mL), which yielded a maximal response equivalent to that of 5 mmol/L LacNAc, as we observed previously (8) . GM-CT-01 was thus at least 1,000 times more potent than LacNAc on molar basis. No growth inhibition was observed when 2 T-cell clones were cultured for 7 weeks in the presence of up to 2.6 mmol/L of GM-CT-01 ( Supplementary Fig. S1 ). Two melanoma cell lines were also cultured for 25 days with GM-CT-01. Growth inhibition was observed starting at day 7 for only one of the melanoma cell lines at the concentration of 2.6 mmol/L. We concluded that GM-CT-01 effects reported below are not affected by toxicity.
þ and CD4 þ TIL from patients with various cancers CD8 þ TIL were isolated from ascites obtained from 27 patients bearing tumors of different histologic origins: melanoma, biliary tract, prostate, esophagus, liver, colon, pancreas, and ovary (Fig. 2) . We also isolated CD4 þ TIL from 11 of the 27 ascites. T cells were incubated with GM-CT-01 or LacNAc for 2 or 20 hours and subsequently stimulated overnight with CD3/CD28 beads. GM-CT-01 boosted IFN-g secretion by more than 3-fold in 22 of the CD8 þ TIL isolates (81%; Fig. 2A ). Treatment with LacNAc had a similar effect, except for 2 patients that only responded to LacNAc ( Fig. 2A) . Incubation of CD4 þ TIL in the presence of GM-CT-01 boosted IFN-g secretion by more than 3-fold in 5 of the 11 cultures but had no effect for the other isolates (Fig. 2B) . GM-CT-01 treatment was also applied to T cells isolated from the blood of donors without cancer. CD8 þ and CD4 þ blood T cells were incubated for 2 hours with GM-CT-01 before an overnight stimulation with CD3/CD28 beads (Fig. 2C ). There was no consistent effect of GM-CT-01 or LacNAc on IFN-g secretion. We concluded that the galectin antagonist had no effect on the IFN-g secretion by blood T lymphocytes from donors without cancer but induced a robust response in the majority of CD8 þ TIL and in half of CD4 þ TIL, by rapid relaxation of galectin-sensitive repression. In addition to IFN-g, the secretion of other cytokines was also tested (Supplementary Table S1 ). In comparison with untreated cells, most samples of GM-CT-01-and LacNAc-treated cells also secreted more IL-2 and TNF-a, but we measured only very minor changes in IL-4 and IL-10. LacNAc triggered a significant cytotoxicity against both P815 bearing anti-CD3 and autologous tumor cell targets (Fig. 3A) . The cytotoxicity of CD8 þ blood T cells, obtained from donors without cancer, was $10-fold more potent than that of TIL and was similar for treated and untreated cells. Degranulation, a prerequisite for cytolysis, was also measured. The percentage of degranulating cells was estimated by surface expression of CD107a and CD107b, which reside at rest in cytolytic granules and, upon activation, are mobilized to the cell surface by exocytosis. After stimulation by P815 cells covered with anti-CD3 antibodies or anti-CD3/CD28 beads, the percentage of CD107 þ cells was low in untreated TIL and strongly increased in TIL treated by GM-CT-01 or LacNAc, but high and equivalent for treated and untreated blood CD8 þ T cells ( Fig. 3B and Supplementary Fig. S2 ). We concluded that GM-CT-01 was as potent as LacNAc to restore cytotoxicity in fresh CD8 þ TIL.
The CD8 þ TIL responding to galectin antagonists harbor poly-LacNAc motifs and galectin-3 To explain how galectin antagonists boost TIL function, we hypothesized that (i) TIL had been recently activated by contact with tumor antigen so that the N-glycans include larger LacNAc oligomers-the natural galectin-3 ligandson surface glycoproteins as compared with resting T cells (44), and (ii) binding of extracellular galectin-3 on surface glycoproteins favors galectin-3-glycoprotein lattices, thereby reducing the motility of surface glycoproteins and consequently impairing TIL functions. This extracellular galectin-3 could be secreted, for example, by the activated T cells or captured by contact with tumor cells or macrophages covered by galectin-3. We decided to test if TIL responding to galectin antagonists were those harboring more LacNAc motifs and more galectin-3. CD8 TIL were isolated from ascites obtained from a patient with ovarian carcinoma, and double labeled with an anti-galectin-3 antibody and with LEL, a lectin that recognizes LacNAc oligomers. Four subpopulations of TIL expressing different levels of galectin-3 and LEL were sorted by flow cytometry (Fig. 4) . Cells from each subpopulation were treated for 2 hours with GM-CT-01 or LacNAc, and stimulated overnight with CD3/CD28 beads. The top 8% of the TIL expressing galectin-3 and LEL ligand motifs secreted almost no IFN-g compared with galectin-3 low LEL low cells. Treatment with either GM-CT-01 or LacNAc had no effect on galectin-3 low LEL low TIL but boosted IFN-g secretion of galectin-3 high LEL high TIL up to the level of galectin-3 low-LEL low TIL (Fig. 4 for IFN-g and Supplementary Table S1 for other cytokines). The next 4% of the TIL secreted intermediate levels of IFN-g in the absence of a treatment with a galectin antagonist. We tentatively concluded that galectin antagonists boosted cytokine secretion specifically in galectin-3 high LEL high TIL.
GM-CT-01 does not detach galectins from cells but disorganizes galectin-glycoprotein lattices
Because we previously observed that LacNAc detaches galectin-3 from cells (8), we tested if GM-CT-01 has the same effect in TIL, which usually express low levels of galectins at cell surface, and in a melanoma cell line for which galectin-3 surface expression is abundant ( Fig. 5 and Supplementary Fig. S3 ). Cells were incubated for 2 hours with GM-CT-01 or LacNAc, labeled with specific anti-galectin antibodies, and analyzed by flow cytometry for surface expression of galectins. As previously reported, labeling of TIL for galectin-3 or galectin-1 decreased after LacNAc treatment (8), but we did not observe galectin detachment after GM-CT-01 treatment (Fig. 5) . This difference was even more striking for melanoma cells (Supplementary Fig. S3 ).
To explain that GM-CT-01 treatment, which failed to detach galectins, nevertheless increased the ability of TIL to secrete IFN-g we examined if GM-CT-01 treatment could disorganize galectin-glycoprotein lattices enough to improve TIL function but not to result into galectin detachment. To this aim, we used a microscopy-based FRET approach that probes close contact between TCR and CD8 molecules at the surface of CD8 þ TIL, hereafter referred to as colocalization. Indeed, we had previously observed a poor colocalization of TCR and CD8 at the surface of CD8 þ TIL, as compared with CD8 þ blood T cells. Moreover, treating CD8 þ TIL with LacNAc increased both IFN-g secretion and the colocalization of TCR with coreceptor CD8 (8, 24) . Here, CD8 þ TIL freshly isolated from ascites were treated overnight with GM-CT-01 or LacNAc, attached to coverslips, and double-labeled with an anti-TCR-b antibody coupled to an acceptor fluorochrome and with an anti-CD8-a antibody coupled to a donor fluorochrome. Upon excitation at donor wavelength, energy can be transferred from the donor to the acceptor if the 2 fluorochromes are closer than $10 nm. In these conditions, full acceptor bleaching abrogates the energy loss, thus increasing donor emission. Data are shown in Table 1 indicate partial bleaching of the donor fluorochrome during the procedure. For 2 of the treated TIL, VUB155, and GHC9, there was a consistent strong increase in donor emission after photobleaching, indicating TCR:CD8 colocalization upon LacNAc and GM-CT-01 treatment. The response to treatments was mild with TIL GHC8. Although modest at first sight, these increases are within the range reported in the literature (8, 24) . We conclude that the increased TCR:CD8 colocalization observed after GM-CT-01 treatment is in agreement with the hypothesis that this treatment disorganizes galectin-glycoprotein lattices without detaching galectins from the cell surface.
Efficacy of different galactomannans for boosting TIL functions
GM-CT-01 is obtained by hydrolysis of guar gum, a galactomannan extracted from guar beans (Cyamopsis tetraglonoloba). The guar gum backbone is a linear chain of b 1.4-linked mannose residues to which galactose residues are 1.6-linked to mannose, forming short side-branches. The guar gum used to obtain GM-CT-01 has a mannose-togalactose ratio of about 1.7. Considering that a large number of plant-derived galactomannans have the same mannose backbone but different mannose-to-galactose ratios, we wondered if different galactomannans would be able to boost TIL function.
The nonhydrolyzed guar gum was inefficient for boosting TIL function (Supplementary Fig. S4A ). We tested partially hydrolyzed guar gum generously provided by Galectin Therapeutics, the company producing GM-CT-01, and also tested a guar gum that we hydrolyzed using a protocol set up in the laboratory (Supplementary Fig. S4B ). It seemed that hydrolyzed guar gum with fragments of about 44 to 50 kDa were able to boost the function of TIL (Supplementary Fig. S4A) .
We subsequently tested a number of galactomannans obtained from various plants, either before or after partial hydrolyzation. None of them, except guar gum in its hydrolyzed version, was able to boost TIL function (Supplementary Fig. S4C ). We tentatively concluded that both the size and the structure of the galactomannan are important for its ability to boost TIL function.
Discussion
This study was prompted by the need for a galectin antagonist approved for clinical use and able to boost TIL function ex vivo. We here reported that treating TIL obtained from patients with various cancers with GM-CT-01, a galactomannan extracted from guar gum, boosted IFN-g secretion upon ex vivo stimulation in $80% of the CD8 þ TIL samples and $50% of the CD4 þ TIL samples. Increased
IFN-g secretion by CD8
þ TIL induced by GM-CT-01 was concentration-dependent and correlated with cytotoxicity. The efficacy of GM-CT-01 for boosting IFN-g secretion seems to be equivalent to that of 2 other galectin antagonists, LacNAc and modified citrus pectin GCS-100 (8 How does GM-CT-01 trigger IFN-g secretion? Galectin-1 and -3 are abundantly released by tumor cells and macrophages, so as to reach nanomolar concentrations in ascites and readily bind to TIL. Our working hypothesis is that a high percentage of isolated TIL have been recently activated, and therefore harbor a glycome with many LacNAc motifs, the natural ligands of galectin-1 and galectin-3 (44) . The abundance of LacNAc motifs and galectins would favor the formation of galectin-glycoprotein lattices at the TIL surface and result in a decreased surface motility of molecular actors of T cell activation. This hypothesis is supported by the lower secretion of IFN-g by galectin-3 high LEL high as compared with galectin-3 low LEL low TIL, and by the selective response of the galectin-3 high LEL high TIL to LacNAc or GM-CT-01. This indicates that upon activation, more galectin-3 binds to TIL expressing glycoproteins bearing more LacNAc motifs and suggests that the dysfunction is related to the presence of galectin-3. LacNAc is able to detach both galectin-1 and galectin-3. Our previous observation that a galectin-3 antibody, which also detached galectin-3 from TIL surface, was able to boost IFN-g secretion by TIL as efficiently as LacNAc, indicated that detaching galectin-3 from TIL is sufficient to restore function, while not excluding a contribution of other galectins, in particular galectin-1 (8) .
How to reconcile this scenario with the failure of GM-CT-01 to detach galectin-1 and galectin-3 from the cell surface? First, LacNAc and GCS-100 interact with galectins by binding to their carbohydrate recognition domains. They are true competitors, whereas GM-CT-01 interacts with a site of galectin-1 opposite to the carbohydrate recognition domain and thus acts as an allosteric antagonist (47) . The galectin-1 site interacting with GM-CT-01 is conserved in the galectin-3 protein (48) . In line with these reports, 2 other studies have shown that the binding of oligomannan to galectin-3 cannot be completed by lactose (49, 50) . Second, acute treatment of TIL with GM-CT-01 resulted in increased TCR:CD8 þ colocalization based on FRET, such as LacNAc and GCS-100. We thus tentatively conclude that GM-CT-01 interacts with galectin-3 without causing its detachment from the TIL surface, but that this interaction results in disruption of glycoprotein:galectin lattices, therefore restoring motility of surface receptors implicated in T-cell activation.
In tumor-bearing mice vaccinated with a tumor antigen, we have previously shown as preliminary data that injections of modified citrus pectin GCS-100 led to tumor rejection in half of the mice (8) . In the same experimental setting, GM-CT-01 failed to confer any tumor rejection (data not shown). However, the experiments with GCS-100 were not extended to test whether T cells from tumorbearing mice were dysfunctional because of glycoproteingalectin lattices and whether GCS-100 treatments disrupted these lattices. Noteworthy murine T cells, as compared with human T cells, seem to be poor in tri-and tetra-antennary poly-LacNac glycans and therefore less susceptible to galectin-mediated dysfunction (44, 51, 52) . GCS-100 could as well have increased apoptosis of tumor cells or inhibited neoangiogenesis and metastases formation, independently of an effect on the immune system as it was reported for modified citrus pectin in other experiments (53) (54) (55) .
It remains remarkable that a short treatment of but a few hours with GM-CT-01 was sufficient to boost, if not fully restore, human TIL functional capacities. Moreover, responsiveness of the vast majority of samples suggests that treatment with galectin antagonists, in particular GM-CT-01, could be effective in patients with cancer to correct impaired TIL functions.
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